Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2022-11-09 00:00:00 ET · period of report 2022-11-07 · accession 0001628280-22-029215 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-09 | 2022-11-07 | AUPH | Martin Michael Robert | Chief Business Off | P - Purchase | $5.16 | +30.0K | 89.5K | +50% | +$154.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-07 | P | A | 30,000 | $5.16 | 89,512 | D | — | — | (F1) The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.98 to $5.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |